Business Description
Y-mAbs Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US9842411095
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 55.42 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 10.76 | |||||
Beneish M-Score | -1.14 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 55.5 | |||||
3-Year EBITDA Growth Rate | 42.3 | |||||
3-Year EPS without NRI Growth Rate | 45.2 | |||||
3-Year FCF Growth Rate | 35.1 | |||||
3-Year Book Growth Rate | -3.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 13.72 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 62.44 | |||||
9-Day RSI | 53.26 | |||||
14-Day RSI | 51.05 | |||||
6-1 Month Momentum % | 208.56 | |||||
12-1 Month Momentum % | 176.02 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.52 | |||||
Quick Ratio | 5.27 | |||||
Cash Ratio | 3.91 | |||||
Days Inventory | 211.1 | |||||
Days Sales Outstanding | 78.9 | |||||
Days Payable | 280.98 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | 0.14 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.54 | |||||
Operating Margin % | -30.27 | |||||
Net Margin % | -25.26 | |||||
FCF Margin % | -32.11 | |||||
ROE % | -20.49 | |||||
ROA % | -16.04 | |||||
ROIC % | -109.96 | |||||
ROC (Joel Greenblatt) % | -315.33 | |||||
ROCE % | -23.44 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 7.9 | |||||
PB Ratio | 6.68 | |||||
Price-to-Tangible-Book | 6.86 | |||||
EV-to-EBIT | -22.85 | |||||
EV-to-EBITDA | -23.53 | |||||
EV-to-Revenue | 6.92 | |||||
EV-to-Forward-Revenue | 6 | |||||
EV-to-FCF | -21.5 | |||||
Price-to-Net-Current-Asset-Value | 7.99 | |||||
Price-to-Net-Cash | 12.97 | |||||
Earnings Yield (Greenblatt) % | -4.38 | |||||
FCF Yield % | -4.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:YMAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Y-mAbs Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 84.819 | ||
EPS (TTM) ($) | -0.49 | ||
Beta | 0.34 | ||
Volatility % | 100.41 | ||
14-Day RSI | 51.05 | ||
14-Day ATR ($) | 0.941764 | ||
20-Day SMA ($) | 15.0165 | ||
12-1 Month Momentum % | 176.02 | ||
52-Week Range ($) | 4.6 - 20.9 | ||
Shares Outstanding (Mil) | 43.78 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Y-mAbs Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Y-mAbs Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Y-mAbs Therapeutics Inc Frequently Asked Questions
What is Y-mAbs Therapeutics Inc(YMAB)'s stock price today?
When is next earnings date of Y-mAbs Therapeutics Inc(YMAB)?
Does Y-mAbs Therapeutics Inc(YMAB) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |